Prm1 - Validation of Alternative “Surrogate” Clinical Endpoints in Advanced Melanoma

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2126
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Surrogate Endpoints for Efficacy in Clinical Research: Working Definitions and Validation

AACR Education book
2008English

Statistical Evaluation of Surrogate Endpoints in Clinical Studies

2014English

Surrogate Endpoints in Advanced Sarcoma Trials: A Meta-Analysis

Oncotarget
Oncology
2018English

A Perspective on Surrogate Endpoints in Controlled Clinical Trials

Statistical Methods in Medical Research
Health Information ManagementEpidemiologyStatisticsProbability
2004English

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria

PLoS ONE
Multidisciplinary
2017English

Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus

Endocrine, Metabolic and Immune Disorders - Drug Targets
EndocrinologyAllergyImmunologyMetabolismDiabetes
2009English

Abstracts of the NIH-FDA Conference “Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications”

Disease Markers
BiochemistryMedicineClinical BiochemistryMolecular BiologyGenetics
1998English

Pcn59 - Association Between Hazard Ratios of Surrogate Time-To-Event Endpoints and Overall Survival in Advanced/Metastatic Cancers

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Perioperative Management of ACE Inhibitor Therapy: Challenges of Clinical Decision-Making Based on Surrogate Endpoints

Journal of Hospital Medicine
Internal MedicineCare PlanningHealth PolicyFundamentalsSkillsLeadershipManagementDiagnosisMedicineAssessment
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy